stockportfolio.pro
Stocks / MRK vs NVS
MRK vs NVS
Merck & Co., Inc. and Novartis AG side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Merck & Co., Inc. (MRK) | Novartis AG (NVS) | |
|---|---|---|
| Market cap | $295.4B | $290.6B |
| Revenue (latest FY) | $65.01B | $56.67B |
| Net income (latest FY) | $18.25B | $13.98B |
| Revenue growth (5y CAGR) | 9.4% | 9.3% |
| Net margin | 28.1% | 24.7% |
| Return on equity | 34.7% | 30.3% |
| P/E ratio | 33.7 | 21.8 |
| Dividend yield | 2.8% | 3.2% |
| Profitable years (of last 10) | 10 | 4 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open MRK — free Open NVS — freeFrequently asked questions
Which is bigger, MRK or NVS?
Merck & Co., Inc. is larger by market capitalization — $295.4B versus $290.6B.
Which grows faster, MRK or NVS?
Over the last five fiscal years, Merck & Co., Inc. grew revenue faster — 9.4%/yr versus 9.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.